The Expression and Action of Decay-Accelerating Factor (CD55) in Human Malignancies and Cancer Therapy

Decay-accelerating factor (DAF, CD55) is physiologically acting as an inhibitor of the complement system, but is also broadly expressed in malignant tumours. Here DAF seems to exert different functions beyond its immunological role such as e.g. promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathways and specific seven-span transmembrane receptors (CD97) binding. Therefore, DAF has already become a target for therapy. In this paper we review the role of DAF in human malignancies as described in different basic, diagnostic and experimental therapeutic studies.

• Publication year

  2006

• Venue

  Cellular Oncology

• Publication date

  2006-12-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1155/2006/814816PMID 17167176PMCID 4618202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells.

  2005cited by this paper
• Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma

  2005cited by this paper
• Expression of the epidermal growth factor seven-transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas.

  2005cited by this paper
• Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement‐regulatory proteins CD55 and CD59

  2005cited by this paper
• Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21.

  2005cited by this paper
• Prostaglandin E2 Regulates the Complement Inhibitor CD55/Decay-accelerating Factor in Colorectal Cancer*

  2005cited by this paper
• Selective expression of a splice variant of decay-accelerating factor in c-erbB-2-positive mammary carcinoma cells showing increased transendothelial invasiveness.

  2005cited by this paper
• Human antibody SC-1 reduces disseminated tumor cells in nude mice with human gastric cancer.

  2005cited by this paper
• (Am. J. Respir. Cell Mol. Biol., 32:540-547)Autocrine and Paracrine Regulation of IL-8 Expression in Lung Cancer Cells

  2005cited by this paper
• N‐glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding

  2004cited by this paper
• Complement regulation at the molecular level: the structure of decay-accelerating factor.

  2004cited by this paper
• Systemic Therapy of Malignant Human Melanoma Tumors by a Common Cold-Producing Enterovirus, Coxsackievirus A21

  2004cited by this paper
• The Epidermal Growth Factor-Seven Transmembrane (EGF-TM7) Receptor CD97 Is Required for Neutrophil Migration and Host Defense1

  2004cited by this paper
• Cancer Epidemiol Biomarkers Prev

  2004cited by this paper
• Expression of decay-accelerating factor on synovial lining cells in inflammatory and degenerative arthritides

  2004cited by this paper
• Tyrosine Kinase, p56lck-induced Cell Motility, and Urokinase-type Plasminogen Activator Secretion Involve Activation of Epidermal Growth Factor Receptor/Extracellular Signal Regulated Kinase Pathways*

  2004cited by this paper
• Expression of CD97 and CD55 in human medullary thyroid carcinomas.

  2004cited by this paper
• Generation and Characterization of Monoclonal Antibodies Directed Against the Surface Antigens of Cervical Cancer Cells

  2004cited by this paper
• Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor.

  2003cited by this paper
• Antiadhesive Role of Apical Decay-accelerating Factor (CD55) in Human Neutrophil Transmigration across Mucosal Epithelia

  2003cited by this paper
• Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

  2003cited by this paper
• Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer

  2003cited by this paper
• Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients

  2003cited by this paper
• ADVANCES IN THE DEVELOPMENT OF A RELIABLE ASSAY FOR THE MEASUREMENT OF STOOL DECAY-ACCELERATING FACTOR IN THE DETECTION OF COLORECTAL CANCER

  2002cited by this paper
• bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction.

  2002cited by this paper
• CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas.

  2002cited by this paper
• Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues.

  2002cited by this paper
• Expression of complement regulating factors in gastric cancer cells

  2002cited by this paper
• The Inhibitory Effect of CD46, CD55, and CD59 on Complement Activation After Immunotherapeutic Treatment of Cervical Carcinoma Cells with Monoclonal Antibodies or Bispecific Monoclonal Antibodies

  2002cited by this paper
• Improvements in the measurement of stool decay-accelerating factor in the detection of colorectal cancer.

  2002cited by this paper
• Polymorphic expression of decay‐accelerating factor in human colorectal cancer

  2001cited by this paper
• Regulation of the New Coexpressed CD55 (Decay-Accelerating Factor) Receptor on Stomach Carcinoma Cells Involved in Antibody SC-1–Induced Apoptosis

  2001cited by this paper
• Interactions of CD55 with non-complement ligands.

  2001cited by this paper
• Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer

  2001cited by this paper
• K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement

  2001cited by this paper
• CD55 is over-expressed in the tumour environment

  2001cited by this paper
• Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis.

  2001cited by this paper
• Epidermal growth factor induces expression of decay-accelerating factor in human colonic cancer cells via the mitogen-activated protein kinase pathway.

  2001cited by this paper
• Pigs Express Multiple Forms of Decay-Accelerating Factor (CD55), All of Which Contain Only Three Short Consensus Repeats1

  2000cited by this paper
• Conservation in decay accelerating factor (DAF) structure among primates.

  2000cited by this paper
• Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury.

  2000cited by this paper
• Cytokine‐mediated up‐regulation of CD55 and CD59 protects human hepatoma cells from complement attack

  2000cited by this paper
• Expression of complement regulatory proteins CR1, DAF, MCP and CD59in haematological malignancies

  2000cited by this paper
• CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.

  2000cited by this paper
• [Adjuvant immunotherapy of stomach carcinoma with antibody-induced apoptosis].

  2000cited by this paper
• Decay accelerating factor (CD55): a target for cancer vaccines?

  1999cited by this paper
• Complement resistance of tumor cells: basal and induced mechanisms.

  1999cited by this paper
• Characterization of glycosylphosphatidylinositol-linked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis.

  1999cited by this paper
• Regulation of CD97 protein in thyroid carcinoma.

  1999cited by this paper
• Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue.

  1999cited by this paper
• Molecular and functional analysis of mouse decay accelerating factor (CD55).

  1999cited by this paper
• Kidneys from HDAF transgenic pigs are physiologically compatible with primates.

  1998cited by this paper
• Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement‐mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance

  1998cited by this paper
• Signal transduction via a protein associated with a glycosylphosphatidylinositol-anchored protein, decay-accelerating factor (DAF/CD55).

  1998cited by this paper
• Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor (CD55).

  1998cited by this paper
• Cytokine‐stimulated release of decay‐accelerating factor (DAF; CD55) from HT‐29 human intestinal epithelial cells

  1998cited by this paper
• Activation of T cells via CD55: recruitment of early components of the CD3-TCR pathway is required for IL-2 secretion.

  1998cited by this paper
• Cytokines modulate expression of cell-membrane complement inhibitory proteins in human lung cancer cell lines.

  1998cited by this paper
• Altered expression of membrane inhibitors of complement in human gastric epithelium during Helicobacter‐associated gastritis

  1998cited by this paper
• Antibody binding to individual short consensus repeats of decay-accelerating factor enhances enterovirus cell attachment and infectivity.

  1998cited by this paper
• Characterization of the CD55 (DAF)‐binding site on the seven‐span transmembrane receptor CD97

  1998cited by this paper
• Decay‐accelerating factor (DAF) in stool specimens as a marker of disease activity in patients with ulcerative colitis (UC)

  1998cited by this paper
• A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement.

  1998cited by this paper
• Tumor-specific apoptosis induced by the human monoclonal antibody SC-1: a new therapeutical approach for stomach cancer.

  1998cited by this paper
• Integrin alpha v beta 6 enhances coxsackievirus B1 lytic infection of human colon cancer cells.

  1997cited by this paper
• Complement‐regulatory proteins in ovarian malignancies

  1997cited by this paper
• CD97: a dedifferentiation marker in human thyroid carcinomas.

  1997cited by this paper
• Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma

  1997cited by this paper
• Stimulation of TK1 lymphoma cells via alpha 4 beta 7 integrin results in activation of src-tyrosine- and MAP-kinases.

  1997cited by this paper
• Paroxysmal Nocturnal Hemoglobinuria as a Molecular Disease

  1997cited by this paper
• Stimulation of TK1 Lymphoma Cells via α4β7Integrin Results in Activation of src-Tyrosine- and MAP-Kinases

  1997cited by this paper
• A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells

  1997cited by this paper
• Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease.

  1997cited by this paper
• Response of SCC-12F, a human squamous cell carcinoma cell line, to complement attack.

  1997cited by this paper
• Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.

  1996cited by this paper
• Immunohistochemistry of Complement Response on Human Renal Cell Carcinoma Biopsies

  1996cited by this paper
• The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF)

  1996cited by this paper
• Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).

  1996cited by this paper
• Interleukin 4 acts as an inducer of decay-accelerating factor gene expression in human intestinal epithelial cells.

  1996cited by this paper
• Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor.

  1996cited by this paper
• Signal transduction and glycophosphatidylinositol-linked proteins (lyn, lck, CD4, CD45, G proteins, and CD55) selectively localize in Triton-insoluble plasma membrane domains of human leukemic cell lines and normal granulocytes.

  1996cited by this paper
• dra-related X adhesins of gestational pyelonephritis-associated Escherichia coli recognize SCR-3 and SCR-4 domains of recombinant decay-accelerating factor

  1995cited by this paper
• Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding

  1995cited by this paper
• Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer.

  1995cited by this paper
• Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis.

  1995cited by this paper
• Homologous restriction of complement‐mediated cell lysis can be markedly enhanced by blocking decay‐accelerating factor

  1995cited by this paper
• Membrane regulators of complement activation and their aberrant expression in disease.

  1995cited by this paper
• Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. Duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms.

  1995cited by this paper
• Multiple isoforms of guinea pig decay-accelerating factor (DAF) generated by alternative splicing.

  1995cited by this paper
• Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody

  1995cited by this paper
• Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage.

  1994cited by this paper
• Protection of thyroid cancer cells by complement‐regulatory factors

  1994cited by this paper
• Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses.

  1994cited by this paper
• Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria.

  1994cited by this paper
• Characterization of DAF-2, a high molecular weight form of decay-accelerating factor (DAF; CD55), as a covalently cross-linked dimer of DAF-1.

  1994cited by this paper
• Structure and function of decay accelerating factor CD55.

  1994cited by this paper
• Glycosylphosphatidylinositol-anchored proteins are preferentially targeted to the basolateral surface in Fischer rat thyroid epithelial cells

  1993cited by this paper
• Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas.

  1992cited by this paper
• Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies

  1992cited by this paper
• Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1.

  1992cited by this paper

• CD55 may be an important prognostic factor of thymic epithelial tumors: a retrospective study

  2025cites this paper
• Complement regulators as novel targets for anti-cancer therapy: A comprehensive review.

  2025cites this paper
• Core-fucosylated glycoproteins as biomarkers for diagnosing pancreatic ductal adenocarcinoma.

  2025cites this paper
• The Interplay of Complements and their Regulators in the Human Body

  2024cites this paper
• CD55 characterizes regulatory T cells with reduced functionality and is downregulated in rheumatoid arthritis.

  2024cites this paper
• Studying the mechanism underlying lipid metabolism in osteosarcoma based on transcriptomic RNA sequencing and single‐cell data

  2023cites this paper
• Therapeutic hyperthermia regulates complement C3 activation and suppresses tumor development through HSPA5/NFκB/CD55 pathway in nasopharyngeal carcinoma.

  2023cites this paper
• Functional genetic variants in complement component 7 confer susceptibility to gastric cancer

  2022influential citation
• CD55 in cancer: Complementing functions in a non-canonical manner.

  2022cites this paper
• Relación entre la expresión proteínas inhibidoras de complemento y la eficacia de anticuerpos terapéuticos en cáncer colorrectal

  2022cites this paper
• CD55 is upregulated by cAMP/PKA/AKT and modulates human decidualization via Src and ERK pathway and decidualization‐related genes

  2022cites this paper
• A structure-based approach for the development of a bicyclic peptide acting as a miniaturized anti-CD55 antibody.

  2021cites this paper
• Generation of a novel decay accelerating factor (DAF) knock-out rat model using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9), genome editing

  2021cites this paper
• Predicting pleural metastasis by detecting CD55 using an ultrasound-enhanced scintillation proximity assay

  2021cites this paper
• Monoclonal Antibodies for Cancer Immunotherapy

  2020cites this paper
• Marker Identification of the Grade of Dysplasia of Intraductal Papillary Mucinous Neoplasm in Pancreatic Cyst Fluid by Quantitative Proteomic Profiling

  2020cites this paper
• CD36 and CD97 in Pancreatic Cancer versus Other Malignancies

  2020cites this paper
• Association of gene polymorphisms of CD55 with susceptibility to and severity of hand, foot, and mouth disease caused by enterovirus 71 in the Han Chinese population

  2020cites this paper
• Current Understanding of Natural Antibodies and Exploring the Possibilities of Modulation Using Veterinary Models. A Review

  2020cites this paper
• Overexpression of CD55 correlates with tumor progression and poor prognosis in gastric stromal tumors

  2019cites this paper
• OTT_A_195182 4703..4712

  2019cites this paper
• Ultrasound-enhanced scintillation proximity assay for rapid diagnostics.

  2019cites this paper
• The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy

  2019cites this paper
• Yin and Yang of Pluripotency: Results of Analysis of Genes Overexpressed In Tumor-Initiating Cells of Krebs-2 Ascites Carcinoma

  2019cites this paper
• A novel therapeutic anti‑CD55 monoclonal antibody inhibits the proliferation and metastasis of colorectal cancer cells.

  2019cites this paper
• Cancer Stem Cells: Emergent Nature of Tumor Emergency

  2018cites this paper
• Beyond the Role of CD55 as a Complement Component

  2018influential citation
• Beyond the Role of CD 55 as a Complement Component

  2018influential citation
• The dual role of complement in cancer and its implication in anti-tumor therapy.

  2016cites this paper
• Anti‐NeuGcGM3 reactivity: a possible role of natural antibodies and B‐1 cells in tumor immunosurveillance

  2015cites this paper
• CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent

  2015cites this paper
• Proteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells*

  2015cites this paper
• HIF-1alpha regulates CD55 expression in airway epithelium

  2015cites this paper
• Monoclonal Antibodies for Cancer Immunotherapy

  2015cites this paper
• Wilms tumor 1 gene, CD97, and the emerging biogenetic profile of glioblastoma.

  2014cites this paper
• CD55 limits sensitivity to complement-dependent cytolysis triggered by heterologous expression of α-gal xenoantigen in colon tumor cells.

  2014cites this paper
• CD97 is a multifunctional leukocyte receptor with distinct roles in human cancers (Review).

  2013cites this paper
• Increased expression of CD55 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma.

  2012cites this paper
• The Invasion and Metastasis Promotion Role of CD97 Small Isoform in Gastric Carcinoma

  2012cites this paper
• Interactions between complement and cellular mediated mechanisms of monoclonal antibody therapy

  2010cites this paper
• Binding of human antigen R (HuR) to an AU-rich element (ARE) in the 3'untranslated region (3'UTR) reduces the expression of decay accelerating factor (DAF).

  2010cites this paper
• Natural antibodies and cancer.

  2009cites this paper
• Natural human immunoglobulins in cancer immunotherapy.

  2009cites this paper
• Selection of anti-cancer antibodies from combinatorial libraries by whole-cell panning and stringent subtraction with human blood cells.

  2008cites this paper
• Sensitization of Epithelial Cancer Cells with Human Monoclonal Antibodies

  2008cites this paper
• Natural monoclonal antibodies and cancer.

  2008cites this paper
• Serum amyloid A: An acute-phase protein involved in tumour pathogenesis

  2008cites this paper
• hCEACAM1‐4L downregulates hDAF‐associated signalling after being recognized by the Dr adhesin of diffusely adhering Escherichia coli

  2008cites this paper
• Eight-channel iTRAQ Enables Comparison of the Activity of Six Leukemogenic Tyrosine Kinases*S

  2008cites this paper
• Human Decay-Accelerating Factor and CEACAM Receptor-Mediated Internalization and Intracellular Lifestyle of Afa/Dr Diffusely Adhering Escherichia coli in Epithelial Cells

  2008cites this paper
• Natural antibodies and cancer.

  2007cites this paper